Lyme borreliosis vaccination: The facts, the challenge, the future

Trends in Parasitology

Volumn 27, Issue 1, 2011, Pages 40-47

  Schuijt, T J ^a,b,c   Hovius, J W ^a,c   van der Poll, T ^a   van Dam, A P ^d   Fikrig, E ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACARICIDE; BACTERIAL ANTIGEN; DECORIN; FIBRONECTIN; OUTER MEMBRANE PROTEIN; OUTER SURFACE PROTEIN A;

BACTERIAL TRANSMISSION; BORRELIA BURGDORFERI; GENE EXPRESSION; IMMUNE RESPONSE; IXODES; LYME DISEASE; NONHUMAN; ORGANISMS BY LIFE CYCLE STAGE; REVIEW; TICK BORNE ENCEPHALITIS; UPREGULATION; VACCINATION;

ANIMALS; ARACHNID VECTORS; BACTERIAL VACCINES; BORRELIA BURGDORFERI; HUMANS; IXODES; LYME DISEASE;

ARTHROPODA; BORRELIA; BORRELIA BURGDORFERI GROUP; IXODES; IXODIDA; MAMMALIA; SPIROCHAETALES;

EID: 78650540372     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.06.006     Document Type: Review

References (80)

1. Bacon R.M., et al. Surveillance for Lyme disease - United States, 1992-2006. MMWR Surveill. Summ. 2008, 57:1-9.
2. Kotsyfakis M., et al. Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis. J. Biol. Chem. 2006, 281:26298-26307.
3. Daix V., et al. Ixodes ticks belonging to the Ixodes ricinus complex encode a family of anticomplement proteins. Insect. Mol. Biol. 2007, 16:155-166.
4. Narasimhan S., et al. A novel family of anticoagulants from the saliva of Ixodes scapularis. Insect. Mol. Biol. 2002, 11:641-650.
5. Hovius J.W., et al. Salivating for knowledge: potential pharmacological agents in tick saliva. PLoS Med. 2008, 5:e43.
6. Curran K.L., et al. Reduction of nymphal Ixodes dammini (Acari: Ixodidae) in a residential suburban landscape by area application of insecticides. J. Med. Entomol. 1993, 30:107-113.
7. Daniels T.J., et al. Evaluation of host-targeted acaricide for reducing risk of Lyme disease in southern New York state. J. Med. Entomol. 1991, 28:537-543.
8. Graf J.F., et al. Tick control: an industry point of view. Parasitology 2004, 129(Suppl.):S427-442.
9. Schwan T.G., Piesman J. Temporal changes in outer surface proteins A and C of the lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice. J. Clin. Microbiol. 2000, 38:382-388.
10. Pal U., et al. TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi. Cell 2004, 119:457-468.
11. Schuijt T.J., et al. The tick salivary protein Salp15 inhibits the killing of serum-sensitive Borrelia burgdorferi sensu lato isolates. Infect. Immun. 2008, 76:2888-2894.
12. Ramamoorthi N., et al. The Lyme disease agent exploits a tick protein to infect the mammalian host. Nature 2005, 436:573-577.
13. Zhang X., et al. BB0323 function is essential for Borrelia burgdorferi virulence and persistence through tick-rodent transmission cycle. J. Infect. Dis. 2009, 200:1318-1330.
14. Brissette C.A., et al. Borrelia burgdorferi RevA antigen binds host fibronectin. Infect. Immun. 2009, 77:2802-2812.
15. Liang F.T., et al. Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses. Infect. Immun. 2004, 72:5759-5767.
16. Probert W.S., Johnson B.J. Identification of a 47 kDa fibronectin-binding protein expressed by Borrelia burgdorferi isolate B31. Mol. Microbiol. 1998, 30:1003-1015.
17. Brissette C.A., et al. Borrelia burgdorferi infection-associated surface proteins ErpP, ErpA, and ErpC bind human plasminogen. Infect. Immun. 2009, 77:300-306.
18. Liang F.T., et al. Molecular adaptation of Borrelia burgdorferi in the murine host. J. Exp. Med. 2002, 196:275-280.
19. Zhang J.R., et al. Antigenic variation in Lyme disease Borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997, 89:275-285.
20. Pausa M., et al. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule. J. Immunol. 2003, 170:3214-3222.
21. Brissette C.A., et al. Lyme borreliosis spirochete Erp proteins, their known host ligands, and potential roles in mammalian infection. Int. J. Med. Microbiol. 2008, 298(Suppl. 1):257-267.
22. Fikrig E., et al. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect. Immun. 1992, 60:773-777.
23. de Silva A.M., et al. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J. Exp. Med. 1996, 183:271-275.
24. Steere A.C., et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med. 1998, 339:209-215.
25. Alexopoulou L., et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat. Med. 2002, 8:878-884.
26. Nassal M., et al. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Int. J. Med. Microbiol. 2008, 298:135-142.
27. LaFleur R.L., et al. Bacterin that induces anti-OspA and anti-OspC Borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin. Vaccine Immunol. 2009, 16:253-259.
28. Gilmore R.D., et al. Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect. Immun. 1996, 64:2234-2239.
29. Earnhart C.G., et al. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains. Vaccine 2007, 25:466-480.
30. Hanson M.S., Edelman R. Vaccines against Lyme disease. New generation vaccines 2004, vol. 3:487-498. Marcel Dekker AG, New York, N.Y.
31. Hanson M.S., et al. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect. Immun. 1998, 66:2143-2153.
32. Hagman K.E., et al. Decorin-binding protein A (DbpA) of Borrelia burgdorferi is not protective when immunized mice are challenged via tick infestation and correlates with the lack of DbpA expression by B. burgdorferi in ticks. Infect. Immun. 2000, 68:4759-4764.
33. Fikrig E., et al. OspB antibody prevents Borrelia burgdorferi colonization of Ixodes scapularis. Infect. Immun. 2004, 72:1755-1759.
34. Fikrig E., et al. Evasion of protective immunity by Borrelia burgdorferi by truncation of outer surface protein B. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:4092-4096.
35. Fikrig E., et al. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect. Immun. 1992, 60:657-661.
36. LaRocca T.J., et al. The bactericidal effect of a complement-independent antibody is osmolytic and specific to Borrelia. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:10752-10757.
37. Tyson K., et al. Biochemical and functional characterization of Salp20, an Ixodes scapularis tick salivary protein that inhibits the complement pathway. Insect. Mol. Biol. 2007, 16:469-479.
38. Fikrig E., et al. Arthropod- and host-specific Borrelia burgdorferi bbk32 expression and the inhibition of spirochete transmission. J. Immunol. 2000, 164:5344-5351.
39. Hanson M.S., et al. Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis. Infect. Immun. 2000, 68:6457-6460.
40. Brown E.L., et al. Multicomponent Lyme vaccine: three is not a crowd. Vaccine 2005, 23:3687-3696.
41. Nadelman R.B., Wormser G.P. Reinfection in patients with Lyme disease. Clin. Infect. Dis. 2007, 45:1032-1038.
42. Stubs G., et al. Acylated cholesteryl galactosides are specific antigens of Borrelia causing lyme disease and frequently induce antibodies in late stages of disease. J. Biol. Chem. 2009, 284:13326-13334.
43. Stubs G., et al. Chemoenzymatic synthesis of a glycolipid library and elucidation of the antigenic epitope for construction of a vaccine against Lyme disease. Chemistry 2010, 16:3536-3544.
44. Trager W. Acquired immunity to ticks. J. Parasitol. 1939, 25:57-81.
45. Narasimhan S., et al. Immunity against Ixodes scapularis salivary proteins expressed within 24hours of attachment thwarts tick feeding and impairs Borrelia transmission. PLoS ONE 2007, 2:e451.
46. Bell J.F., et al. Resistance to tick-borne Francisella tularensis by tick-sensitized rabbits: allergic klendusity. Am. J. Trop. Med. Hyg. 1979, 28:876-880.
47. Nazario S., et al. Prevention of Borrelia burgdorferi transmission in guinea pigs by tick immunity. Am. J. Trop. Med. Hyg. 1998, 58:780-785.
48. Valle M.R., et al. Integrated control of Boophilus microplus ticks in Cuba based on vaccination with the anti-tick vaccine Gavac. Exp. Appl. Acarol. 2004, 34:375-382.
49. Burke G., et al. Hypersensitivity to ticks and Lyme disease risk. Emerg. Infect. Dis. 2005, 11:36-41.
50. Wikel S.K., et al. Infestation with pathogen-free nymphs of the tick Ixodes scapularis induces host resistance to transmission of Borrelia burgdorferi by ticks. Infect. Immun. 1997, 65:335-338.
51. Trimnell A.R., et al. A cross-reactive tick cement antigen is a candidate broad-spectrum tick vaccine. Vaccine 2005, 23:4329-4341.
52. Labuda M., et al. An antivector vaccine protects against a lethal vector-borne pathogen. PLoS Pathog. 2006, 2:e27.
53. Canales M., et al. Vaccination with recombinant Boophilus annulatus Bm86 ortholog protein, Ba86, protects cattle against B. annulatus and B. microplus infestations. BMC Biotechnol. 2009, 9:29.
54. Canales M., et al. Conservation and immunogenicity of the mosquito ortholog of the tick-protective antigen, subolesin. Parasitol. Res. 2009, 105:97-111.
55. de la Fuente J., et al. Reduction of tick infections with Anaplasma marginale and A. phagocytophilum by targeting the tick protective antigen subolesin. Parasitol. Res. 2006, 100:85-91.
56. Hajdusek O., et al. Knockdown of proteins involved in iron metabolism limits tick reproduction and development. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1033-1038.
57. Hajdusek O., et al. Characterization of ferritin 2 for the control of tick infestations. Vaccine 2010, 28:2993-2998.
58. Kotsyfakis M., et al. Cutting edge: immunity against a "silent" salivary antigen of the Lyme vector Ixodes scapularis impairs its ability to feed. J. Immunol. 2008, 181:5209-5212.
59. Prevot P.P., et al. Exosites mediate the anti-inflammatory effects of a multifunctional serpin from the saliva of the tick Ixodes ricinus. FEBS J. 2009, 276:3235-3246.
60. Prevot P.P., et al. Anti-hemostatic effects of a serpin from the saliva of the tick Ixodes ricinus. J. Biol. Chem. 2006, 281:26361-26369.
61. Prevot P.P., et al. Protective immunity against Ixodes ricinus induced by a salivary serpin. Vaccine 2007, 25:3284-3292.
62. Valenzuela J.G., et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J. Exp. Med. 2001, 194:331-342.
63. Zeidner N., et al. Suppression of acute Ixodes scapularis-induced Borrelia burgdorferi infection using tumor necrosis factor-alpha, interleukin-2, and interferon-gamma. J. Infect. Dis. 1996, 173:187-195.
64. Levi M., van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc. Med. 2005, 15:254-259.
65. Decrem Y., et al. The impact of gene knock-down and vaccination against salivary metalloproteases on blood feeding and egg laying by Ixodes ricinus. Int. J. Parasitol. 2008, 38:549-560.
66. Francischetti I.M., et al. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 2002, 99:3602-3612.
67. Decrem Y., et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J. Exp. Med. 2009, 206:2381-2395.
68. Hoffmann A., et al. Isolation and characterization of a thrombin inhibitor from the tick Ixodes ricinus. Pharmazie 1991, 46:209-212.
69. Anguita J., et al. Salp15, an Ixodes scapularis salivary protein, inhibits CD4(+) T cell activation. Immunity 2002, 16:849-859.
70. Hovius J.W., et al. Salp15 binding to DC-SIGN inhibits cytokine expression by impairing both nucleosome remodeling and mRNA stabilization. PLoS Pathog. 2008, 4:e31.
71. Hovius J.W., et al. Tick-host-pathogen interactions in Lyme borreliosis. Trends Parasitol. 2007, 23:434-438.
72. Dai J., et al. Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent. Cell Host Microbe 2009, 6:482-492.
73. Narasimhan S., et al. A tick antioxidant facilitates the Lyme disease agent's successful migration from the mammalian host to the arthropod vector. Cell Host Microbe 2007, 2:7-18.
74. Sukumaran B., et al. An Ixodes scapularis protein required for survival of Anaplasma phagocytophilum in tick salivary glands. J. Exp. Med. 2006, 203:1507-1517.
75. Wang H., Nuttall P.A. Immunoglobulin-binding proteins in ticks: new target for vaccine development against a blood-feeding parasite. Cell Mol. Life Sci. 1999, 56:286-295.
76. Vaughan J.A., et al. Kinetics of ingested host immunoglobulin G in hemolymph and whole body homogenates during nymphal development of Dermacentor variabilis and Ixodes scapularis ticks (Acari: Ixodidae). Exp. Appl. Acarol. 2002, 27:329-340.
77. Little S.E., et al. Lyme borreliosis in dogs and humans in the USA. Trends Parasitol. 2010, 26:213-218.
78. Topfer K.H., Straubinger R.K. Characterization of the humoral immune response in dogs after vaccination against the Lyme borreliosis agent. A study with five commercial vaccines using two different vaccination schedules. Vaccine 2007, 25:314-326.
79. Levy S.A., et al. Infection rates in dogs vaccinated and not vaccinated with an OspA Borrelia burgdorferi vaccine in a Lyme disease-endemic area of Connecticut. Int. J. Appl. Res. Vet. Med. 2005, 3:1-5.
80. LaFleur R.L., et al. One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin. Clin. Vaccine Immunol. 2010, 17:870-874.